🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — April 14, 2026

Across 50 8-K filings from April 14, 2026, dominant themes include a surge in M&A activity (8 deals: take-privates, mergers, JVs valued at >$2B total), extensive board/officer changes (25+ resignations/appointments, mostly neutral/positive for strategic alignment), and mixed financing events ($1.5B+ raised via equity/debt/credit but 4 distress signals). Period-over-period trends where disclosed show resilience (Assertio continuing ops revenue +9.7% YoY to $68.2M despite wider $31.3M net loss; no declines in 40/50 filings) but outliers like SunPower (GAAP revenue $300M down with margins -600bps to 43%) and Hydrofarm (interest default Jan 2026). Critical developments: Avanos 72% premium takeover ($1.27B EV), Lucid $750M funding+CEO shift, Horizon-Monroe BDC merger ($471M pro forma NA); bearish Hydrofarm forbearance, CERO dilutive note. Portfolio-level: Energy transition (6 filings) bullish on $1B+ rev targets; healthcare M&A active; BDCs consolidating. Implications: Arbitrage opps in deals, watch liquidity in small caps, positive capital alloc (Dow 459th div, CareCloud $3.2M savings).

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 14, 2026

Across 50 filings dated April 14, 2026, for the USA Dow Jones 30 stream, institutional 13F-HR reports (25+ filings) reveal overwhelming conviction in mega-cap tech with NVDA, AAPL, MSFT, and AMZN comprising top holdings in $100B+ portfolios, signaling sustained bullish bias amid no reported changes QoQ. Blue-chip earners show resilience: JNJ Q1 sales +9.9% YoY (raised FY2026 guidance to $100.8B, +7%), JPM net income +13% YoY ($16.5B), but mixed EPS/FCF trends (JNJ GAAP NI -52%). Healthcare catalysts dominate with Travere's first-ever FSGS FDA approval (46% proteinuria cut) and Avanos $1.27B buyout at 72% premium; energy M&A surges via XCF/DevvStream/Southern merger targeting $1B rev by Jun 30. Small caps flash distress: Hydrofarm loan forbearance post-default, Alphega loss +92% YoY, American Battery ICFR weaknesses. Capital allocation favors dividends (Unity +7%, Dow 459th consecutive $0.35, Ohio Valley $0.25). Portfolio trends: Revenue +10-20% YoY avg in reporters, but margins mixed (-7% gross AstroNova); DJ30-exposed names (JNJ, JPM, DOW) outperform small caps, implying buy blue-chips, avoid distressed.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 14, 2026

Across 50 SEC filings for April 14, 2026, dominant themes include a surge in M&A activity particularly in biotech/healthcare (Avanos, Day One, Kezar) and energy transition (DevvStream/XCF/Southern mergers), mixed bank earnings with YoY growth but QoQ softness (Unity Bancorp +23% YoY NI, Wells Fargo +7% YoY), and revenue declines in small caps/industrials (Northann -11% YoY, SemiLEDs -90% YoY Q revenue). Period-over-period trends show 6/15 earnings filings with YoY revenue growth averaging +9% but QoQ mixed (-2% avg), margin compressions in 5/10 (avg -100bps), and positive capital returns like Unity's 7% dividend hike and Wells Fargo's $4B buyback. Neutral 13F filings (9 total) reveal persistent tech concentration (NVDA top in 4 portfolios). Critical developments: Travere's FDA approval for FILSPARI (46% proteinuria reduction), Westlake's $67M antitrust settlement, and Hydrofarm's debt forbearance signal sector risks. Portfolio-level: Healthcare M&A premiums average 70%+, energy backlog builds through 2030, but microcaps face restatements/declines; actionable now on catalysts like H2 2026 deal closes.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 14, 2026

Across 50 SEC filings from April 14, 2026, primarily non-Consumer Discretionary but including financials, energy, tech, and SPACs, key themes emerge in M&A activity (7 deals with positive/mixed sentiment), stable institutional 13F holdings heavily tilted to ETFs/tech (9 filings showing no changes), and mixed financial performance with revenue growth in 5/12 reporting companies (avg +27% YoY) offset by widening losses in development-stage firms. Period-over-period trends show YoY revenue gains (e.g., Full Truck Alliance +11.1%, Digital Brand Media +40.1% Q1) but margin pressures and rising provisions (Wells Fargo provisions +1094% YoY to $11.1B); capital allocation leans positive with dividend hikes (FNB +8%) and buybacks ($250M new program). Critical developments include merger closures (Horizon Technology positive) and distress signals (Hydrofarm forbearance, Gulf Resources 10-K delay), implying opportunities in consolidations but risks in liquidity-constrained names. Portfolio-level patterns: 6/10 financial filings bullish on returns to shareholders, contrasting negative debt events in 3 energy/industrials; no S&P 500 Consumer Discretionary pure-plays but cross-sector insights flag M&A as a growth driver amid stable institutional conviction.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights reveal mixed Q1 2026 performance with Johnson & Johnson posting 9.9% YoY sales growth but 52.4% GAAP EPS decline, offset by raised FY2026 guidance (sales +7.0%, EPS +7.1%); biotech sector shows M&A momentum (Kezar tender at $6.955/share + CVR) and catalysts (Praxis NDA accepted, PDUFA Jan 29 2027). Aggregate trends indicate revenue acceleration in pharma (JNJ +9.9%, BeOne +40.2% YoY to $5.343B) but widening losses in pre-clinical biotechs (Accustem net loss +16.7% to $1.756M). Non-healthcare filings dominate (31/50 are 13F-HR neutral snapshots heavy in ETFs/tech like Apple/MSFT/NVDA, no changes), signaling advisor caution or stability; capital raises proliferate (Lucid $550M, Cingulate resale registration). Portfolio-level: 5/10 key healthcare firms raised/reiterated guidance, but 4/10 reported margin dips or expense surges (e.g., New Horizon R&D +867% YoY). Critical implications: Biotech alpha from catalysts/M&A, but dilution risks in small caps; watch advisor 13Fs for healthcare rotations.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 14, 2026

Across 36 DEF 14A proxy statements filed around April 14, 2026, overarching themes include routine elections of directors (e.g., 100% board nominees in most cases), advisory say-on-pay votes, auditor ratifications (e.g., Deloitte, KPMG, E&Y dominant), and frequent amendments to equity incentive plans (e.g., increases in authorized shares for 10+ firms like EOSE, NSP, INSPIRE, ARBT) signaling aggressive talent retention amid 2025's mixed performance. Period-over-period trends show limited but telling data: bullish outliers like Equity Residential's 2.6% YoY Normalized FFO growth ($3.99/share), MyRisk volumes +10% at Myriad Genetics, and Brighthouse's audit fees +0.2% (stable), contrasted by bearish Mattel net sales -1% YoY, Flowers Foods' GAAP EPS $0.40 vs adjusted $1.09 (wide gap), and REGENXBIO's FDA clinical hold (Jan 2026) + CRL (Feb 2026). Sentiment is neutral-dominant (26/36), positive in 5 (EQR, MYGN, NRDS, ADT, TBI), mixed in 5; no widespread insider selling, with ownership guidelines met (e.g., Brighthouse directors hold 2,837-4,556 RSUs, no vested sales). Portfolio-level patterns: REITs outperform on growth (EQR top-quartile NOI +2.2%), biotechs face regulatory hurdles (3/5 mixed), consumer flat/declining; capital returns strong in EQR ($1.38B dividends/buybacks) and TrueBlue (19% share reduction via 6.7M repurchases). Critical implications: Annual meetings (May-June 2026 cluster) as catalysts for comp backlash or plan approvals; watch dilutive share hikes and SPAC liquidation risks for near-term volatility.

36 high priority 36 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 14, 2026

SRx Health Solutions, Inc. (SRXH) dominates the IPO Pipeline stream with its high-materiality (9/10) S-4 filing on April 14, 2026, signaling a pending business combination that could fast-track public listing via merger or de-SPAC structure. The filing discloses unaudited financials for FY2025 (2024-10-01 to 2025-09-30) and Q4 FY2025 (2025-10-01 to 2025-12-31) with prior-year comparatives across Digital, International, and Brick & Mortar revenue channels, highlighting diversification efforts amid customer concentration risks. Neutral sentiment prevails, balanced by crypto asset holdings (Ethereum, Bitcoin) and recent capital raises via private placement (2025-04-24). Key developments include the Halo SpinOut SPV Inc. transaction (2025-08-21) and Common Class A event (2025-04-25), underscoring restructuring for IPO readiness. No quantified period-over-period trends are detailed, but disclosures enable peer benchmarking in healthcare IPOs. Market implications point to near-term catalysts from merger completion, though dilution risks from convertible notes (issued 2025-07-07) and warrants loom large.

1 high priority 1 total filings
· daily

Global High-Priority Regulatory Events — April 14, 2026

Across 50 filings spanning April 14, 2026, a dominant theme is routine SEBI compliance from 18 Indian companies (e.g., Godavari Biorefineries, TD Power Systems) confirming non-Large Corporate status, signaling broad regulatory adherence among smaller/mid-cap firms with low outstanding borrowings (avg <₹100Cr where disclosed), reducing debt fundraising disclosure burdens. High-materiality US-centric events dominate actionability: Avanos Medical's $1.272B takeover at $25/share (72% premium), energy mergers (XCF/DevvStream/Southern targeting $1B rev/$100M EBITDA), contrasted by insolvencies (AGS Transact CIRP updates) and financial deteriorations (Northann rev -11.4% YoY, SemiLEDs -90% YoY). Period trends show mixed revenue (4/12 reporting firms up avg +12% YoY like Full Truck Alliance +11.1%, 5 down avg -35% YoY), pervasive margin compression (Chipmos -580bps to 10.8%, Immersion royalties -84.6% H1 YoY), and positive capital events (Dow 459th dividend, Shriram Fitch 'BBB-' upgrade post-MUFG stake). M&A/takeover volume (6 filings) implies sector consolidation in healthcare/energy, while IEPF defaults (Indian Hume Pipe, Jagsonpal) flag governance risks for unclaimed shareholders. Portfolio implications: overweight M&A targets, avoid distressed ops like Hydrofarm forbearance; catalyst-rich H2 2026 closes drive upside.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 14, 2026

Across 45 SEC filings in the Financial Results & Earnings stream (mostly 10-Q/10-K from small-cap US companies), overarching themes include widespread revenue declines (17/45 companies reported YoY drops averaging -40%, e.g., SemiLEDs -90%, Greystone -76%) and net loss expansions (25/45 widened losses YoY, avg +50%), offset by financing-driven cash boosts in 30+ cases and explosive growth outliers like BITMINE (+390% rev) and ABQQ (+236%). Mixed sentiment prevails (32/45), with SPACs (8 filings) stable via trust income (e.g., Legato IV +$686k net income from investments), while impairments (Saga $20M goodwill, Heritage $118M intangibles) and related-party reliance signal distress. Period trends show QoQ cash improvements in 20 companies (avg +50%) but margin compression (-150bps avg in 12 reporters) and dilution via share issuances (e.g., BITMINE shares doubled). No broad insider trading patterns, but capital allocation leans conservative (dividends cut in Saga -37.5%, Immersion declared $1.5M). Market implications: High volatility in microcaps, alpha in growth outliers amid sector rotation from cyclicals; portfolio caution on trade policy risks (Northann) and going concerns (Greystone, Go Go Buyers).

45 high priority 45 total filings
· daily

US SEC Trading Suspension Halt Orders — April 14, 2026

The single filing in the USA Trading Suspensions stream reveals acute delisting risk for Beasley Broadcast Group, Inc. (BBGI), which received a Nasdaq deficiency notice on April 13, 2026, for failing the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), reporting a $49,330,431 deficit in its December 31, 2025 Form 10-K. No period-over-period financial trends are detailed, but the deficit underscores severe balance sheet deterioration with no alternative listing standards met. Forward-looking risks emphasize no assurance of compliance plan approval by May 28, 2026, or extension to October 10, 2026, potentially leading to trading halt or delisting. Negative sentiment (10/10 materiality) dominates, signaling high portfolio risk for media/broadcast exposure. Investors face immediate implications for liquidity and valuation in suspension-prone small-caps, with ongoing trading under BBGI but elevated downside.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 14, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy intelligence stream (24 new), overarching themes reveal a financing frenzy with 18+ companies securing debt/equity (e.g., $50M CareCloud facility, $550M Lucid investment) to stave off liquidity crunches, contrasted by acute distress signals like Hydrofarm's interest default and Beasley's $49M stockholders' deficit triggering Nasdaq compliance risks. Period-over-period trends are sparse but highlight deteriorations: SunPower's GAAP revenue down $8.8M to $300M YoY with gross margins compressing 600 bps to 43%, Hydrofarm's unpaid interest due Jan 31 2026, and no broad margin expansions despite revenue targets like XCF's $1B fuel rev goal. M&A/take-private activity surges with premiums (Avanos 72%, Globalstar $90/share option), signaling exit opportunities amid distress, while 6 filings show covenant-heavy loans/forbearances maturing 2026-2027. Capital allocation leans toward deleveraging (CareCloud pref redemption saving $3.2M ann dividends) vs reinvestment, with no buybacks/dividends noted. Forward catalysts cluster H2 2026 (Avanos close, urban-gro 10-K filing), implying near-term volatility. Portfolio-level, neutral/positive sentiment dominates (26/36), but mixed/negative in 6 cases flag deepening distress; actionable now: arbitrage M&A spreads, short Nasdaq-deficient names.

36 high priority 36 total filings
· daily

US Executive Officer Management Changes SEC — April 14, 2026

Across 32 filings on US executive and director changes dated April 14, 2026, a dominant theme is proactive board and C-suite refreshes with experienced hires in growth sectors like energy, nuclear, biotech, and EV/autonomy, signaling strategic acceleration toward scaling, innovation, and profitability (e.g., Lucid's CEO hire, Oklo's nuclear experts, Corteva's crop protection CEO). Positive sentiments prevail in 16/32 filings (50%), with high-materiality appointments (8-9/10) in Lucid, Corteva, Harmony, and Invesco Mortgage emphasizing continuity and expertise amid planned successions. Neutral changes dominate resignations (18/32, no disagreements noted), but red flags emerge in mass director exits at Coretec Group (3 resignations) and finance terminations at XCF Global. Forward-looking catalysts include Harmony’s reiterated $1.0-1.04B 2026 revenue guidance, Spok’s $6M annual savings post-10% layoffs, Dow’s 459th consecutive dividend (Q2 payable June 12), and Corteva’s Q4 2026 spin-off with Sept 15 investor day. No broad YoY revenue/margin deterioration, but isolated mixed signals like Spok’s $1.6-2M Q2/Q3 charges highlight restructuring costs; overall, portfolio-level pattern favors bullish continuity in high-conviction sectors over isolated churn.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 14, 2026

Across 32 SEC 8-K filings on USA Board Room Changes (April 14, 2026), the dominant theme is leadership refresh with 18 resignations/departures (mostly neutral, no disagreements cited) and 20+ appointments/promotions of experienced executives/directors, signaling proactive governance evolution amid growth strategies. Positive developments cluster in high-materiality EV/nuclear (Lucid, Oklo), animal health (ImmuCell), and REITs (Invesco), with sentiments averaging positive/neutral (18 positive/mixed, 13 neutral, 1 negative). Capital allocation remains shareholder-friendly: Dow's 459th consecutive quarterly dividend ($0.35/share, record May 29, payable June 12), Spok's >10% yield maintained post-restructuring ($6M annual savings), Harmony's reiterated 2026 revenue guidance ($1.0-1.04B). No widespread period-over-period declines noted; outliers include Spok's Q2/Q3 2026 restructuring charges ($1.6-2M) vs savings. Portfolio implications: Bullish for sectors adding operational/scaling expertise (e.g., 6/10 high-materiality filings), monitor stability in microcaps with mass exits (Coretec); enhances conviction in continuity plays like Otter Tail's succession.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — April 14, 2026

The 13 filings reveal a surge in SPAC activity dominating USA M&A & Takeover space, with 3 new IPOs (Maywood, Apogee, ACP) raising ~$487M gross proceeds in early April 2026, alongside 2 de-SPAC completions (Horizon-Monroe merger closing with $471.7M pro forma assets; Haymaker-Suncrete despite pre-merger $31.5k net losses and going concern doubts). Key period trends include Assertio's pro forma continuing ops revenue +9.7% YoY to $68.2M (2025 vs 2024) but net loss widening 14.2% YoY to $31.3M, offset by $35M asset sale boosting cash to $45.2M and equity to $109.5M; discontinued ops showed $50.5M rev/$11.4M NI pre-sale. Positive sentiments prevail (7/13 positive/neutral), with Horizon announcing $10M buyback, supplemental distributions from July 2026, and $4M fee waivers. Portfolio-level patterns: SPAC fundraising liquidity up ~487M enabling targets in robotics/EVs/fintech; BDC consolidation via Horizon-Monroe adds $24B AUM. Implications: Heightened M&A catalysts short-term, watch SPAC deadlines (e.g., Suncrete July 28) and post-merger integrations for alpha.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 14, 2026

Overnight SEC filings reveal a surge in M&A activity, particularly in healthcare (Avanos acquisition at 72% premium, Kezar tender at $6.955/share + CVR, Day One tender at $21.50/share) and energy transition (XCF/DevvStream/Southern merger targeting $1B revenue/$100M EBITDA), signaling sector consolidation amid growth ambitions. Financial results show mixed trends: 4/10 reporting companies posted YoY net income growth (e.g., Unity Bancorp +23.2%, Wells Fargo +7%), but QoQ declines prevalent (Unity -7.7%, Wells -2%) with margin pressures in semis/manufacturing (AstroNova gross profit -7.4% YoY, Chipmos margins to 10.8%, SemiLEDs revenue -90% YoY). Small caps face headwinds (Northann revenue -11.4% YoY, operating loss -84.2% of revenue; Alphega net loss +92% YoY; Hydrofarm forbearance on $125M loan), while biopharma shines (Travere FDA approval for FILSPARI, 46% proteinuria reduction). 13F filings (10/50) indicate institutional stability with no position changes in most (e.g., SeaTown, Value Investment flat QoQ). Capital returns strong (Unity dividend +7% to $0.16/share, Wells $4B buyback), but risks from settlements (Westlake $67M), restatements (Nature's Miracle), and control weaknesses (American Battery). Portfolio-level: Healthcare/energy bullish, small caps/banks mixed; watch H2 2026 closings and Q2 earnings for catalysts.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 13, 2026

Across 14 filings in the S&P 500 Technology stream, institutional 13F-HRs reveal overwhelming conviction in core tech leaders, with NVDA topping holdings in 4/5 reports (total ~$750M+ exposure), AAPL/MSFT/AMZN following closely in multi-billion portfolios, signaling sustained AI/semi/mega-cap strength amid Q1 2026 positioning. Palo Alto Networks (PANW) stands out with a bullish long-term lease extension for 290k sq ft to 2040 ($13M-$16M annual rent), underscoring cybersecurity expansion. Non-tech filings show mixed trends: Pineapple Financial bolstered balance sheet with $72M funding despite $23M crypto loss (-5.5% rev YoY), Jewett-Cameron posted +4.7-16.4% sales growth but -83.8% gross profit H1 YoY driving $5.2M loss. Proxy materials for Dime/Genco neutral, Pershing Square advances PSUS IPO and $2.1B Q2 2026 M&A for AUM growth, while Replimune faces 2nd FDA CRL setback. Portfolio-level: Revenue growth in 2/4 10-Qs but margin compression/losses dominate small caps; tech signals bullish via institutions/PANW.

5 high priority 9 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 13, 2026

Across 13 SEC filings from NASDAQ-100 constituents and related entities, key themes include divergent financial performances with revenue growth in AI and trading sectors offset by sharp losses from crypto impairments and operational declines; biotech faces regulatory hurdles while proxies signal active governance seasons for banks and shipping. Period-over-period trends show 2/5 financial reporters with revenue growth (AITX +26% YoY, Jewett-Cameron +16.4% YoY Q3) but widespread margin compression (Jewett gross profit -83.8% YoY half-year, Pineapple expenses +820% YoY due to $23M crypto loss) and net losses expanding (Jewett net loss $5.2M half-year vs prior, Pineapple $25.9M). Institutional 13F filings reveal heavy concentration in megacap tech (NVDA, AAPL, MSFT topping portfolios totaling billions), indicating sustained conviction amid volatility. Positive catalysts include board strengthening at CMC and balance sheet fortification at Pineapple via $52M+ financing; risks dominate in crypto (Intchains negative cash flows, no dividends) and biotech (Replimune second FDA CRL). Portfolio-level implications favor selective longs in AI/growth stories and caution on speculative crypto/biotech exposures ahead of proxy votes and earnings.

5 high priority 8 medium 13 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 13, 2026

Across 50 filings from the USA S&P 500 Financials intelligence stream (broadly including banks, insurers, asset managers, and adjacent sectors), dominant themes include robust M&A activity (e.g., Somnigroup-LEG $2.5B all-stock deal, Clear Channel $2.43/share buyout), IPO preparations (Alamar Biosciences, Kailera Therapeutics), and mixed financial results with revenue growth averaging ~60% YoY in reporting small caps (e.g., Alamar 195%, OriginClear 55%) offset by persistent margin compression (avg -200bps in 4/7 detailed firms) and net losses. Biotech/healthcare filings show positive trial catalysts (IDEAYA PFS HR 0.42, Spyre RHI -9.2 pts), while operational disruptions like contract losses (Ameriguard 58% revenue hit) and regulatory setbacks (Replimune 2nd CRL) temper optimism. Capital allocation leans shareholder-friendly with dividend hikes (American States +8.3%) and buybacks (News Corp $1B program), but Nasdaq compliance risks (Sow Good equity < $2.5M) and leadership changes signal caution. Portfolio-level trends reveal 8/15 revenue reporters growing >20% YoY, yet 5/7 margins declining amid SG&A surges; forward catalysts cluster in H2 2026 (FDA NDAs, Phase 3 readouts, merger closes). Overall, actionable alpha lies in M&A arbitrage and biotech turnarounds, with financials showing stable but unexciting EPS growth (e.g., ChoiceOne proxy neutral).

27 high priority 23 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 13, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream, direct staples exposure is limited to Conagra Brands (CEO transition) and Coca-Cola Europacific Partners (share repurchases), amid a broader mix of proxy statements, financial reports, and M&A updates; overarching themes include active proxy season with 15+ DEF/DEFA14A filings seeking director elections and compensation approvals, and resilient revenue growth in small-caps averaging +77% YoY where reported (Envirotech +218%, OriginClear +55%, Elite Express +16%). Period-over-period trends show 6/12 financial filings with YoY revenue gains but mixed margins (e.g., AITX gross margins +1000bps to 71%, Kopin cost/revenue 84.2% stable), offset by cash drains (Elite Express cash -95% QoQ to $68K) and losses (Edgemode net loss +1450% to $24.6M). Capital allocation leans shareholder-friendly with dividends up (Farmer Mac +7% YoY quarterly, KKR FS Income $0.225/share monthly), buybacks (Teleflex $1B from $1.8B divestiture proceeds), and repurchases (CCEP 273K shares). Forward-looking catalysts cluster in H2 2026 (Teleflex divest closes, Perella Weinberg acquisition) and Q2 2026 (Diamond Hill merger), with positive sentiment in 12/50 filings driven by M&A and leadership stability. Portfolio-level patterns flag staples-adjacent strength in food/agri (Conagra $12B sales, Farmer Mac 116% ROE) versus risks in delisting threats and lawsuits, implying selective buying opportunities pre-catalysts.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 13, 2026

Proxy season dominates the 50 filings with over 20 DEF 14A/DEFA14A announcements for annual meetings clustered in May-June 2026, focusing on director elections, auditor ratifications, and compensation votes, mostly neutral sentiment but highlighting governance strengths like 100% board independence at Farmer Mac. Financial disclosures reveal mixed trends: Bancorp assets +8.0% YoY to $9.4B, net income +4.6% to $228M, ROE 29% (up from 27%); Farmer Mac record 116% ROE, book value $112.77 (+YoY), dividend +7%; contrasted by TOFUTTI sales -11.8% YoY to $7.8M, op loss +27.5%; Edgemode net loss ballooned to $24.6M from $1.6M, liabilities x4.2 to $20.1M. Positive catalysts include Leggett & Platt $2.5B all-stock acquisition (0.1455x exchange ratio), IDEAYA Phase 2/3 PFS 6.9mo vs 3.1mo (HR 0.42), Diamondback Q1 hedged oil $72.53/bbl with $133M derivative gain, AITX FY26 rev +26% to $7.75M/margins +10pts to 71%. 13F-HR filings (12 total) show institutional heavy tilt to tech (Apple/MSFT/NVDA top across $10B+ AUM), minimal Industrials exposure. Industrials-specific: Caterpillar director nominee Aug 1, Patterson-UTI LTIP expansion +28.9M shares (overhang to 11.3%), Genco Shipping proxy solicitation. Overall neutral-to-mixed sentiment (avg materiality 5.8/10), with capital allocation favoring dividends/equity plans amid limited M&A/insider data.

21 high priority 29 medium 50 total filings